Joseph Piven is Thomas E. Castelloe Distinguished Professor of Psychiatry and director of the Carolina Institute for Developmental Disabilities at the University of North Carolina at Chapel Hill. He is also director of the NIH Autism Center of Excellence Network’s Infant Brain Imaging Study (IBIS). He served on the American Psychiatric Association committee that wrote the new definition of autism spectrum disorder for the DSM-5.
Joseph Piven
Professor
University of North Carolina at Chapel Hill
From this contributor
Correcting the record: Leo Kanner and the broad autism phenotype
The specter of the ‘refrigerator mother’ theory continues to haunt the history of autism. New information puts Kanner’s observations of parents into context.
Correcting the record: Leo Kanner and the broad autism phenotype
By
James Harris, Joseph Piven
26 April 2016 | 10 min read
Explore more from The Transmitter
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
By
Natalia Mesa
3 June 2026 | 11 min read
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
By
Paul Middlebrooks
3 June 2026 | 1 min read
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
By
Calli McMurray
2 June 2026 | 5 min read